Background: Tissue factor (TF), the main trigger of coagulation is important in the propagation of cardiovascular diseases. Based on an in vitro study, we hypothesised that enalapril may blunt the endotoxin-induced, TF-triggered coagulation in humans. Methods: In a randomised, controlled trial, 30 healthy male volunteers received 2 ng / kg of lipopolysaccharide (LPS) after pre-treatment with placebo or enalapril for 5 days or with enalapril 2 h before LPS infusion. Results: Infusion of LPS increased interleukin-6 levels 400 fold, and induced a 10-fold increase in prothrombin fragment, a fourfold increase in D-dimer, and a fivefold increase in plasmin-antiplasmin complexes. However, pre-treatment with enalapril did not blunt LPS-induced coagulation. Conclusions: Our trial provides evidence against a modulatory role of angiotensin converting enzyme in LPS-induced, TF-triggered coagulation.
. Introduction
factor (TF) induced coagulation increased levels of soluble TF, prothrombin fragment (F ), and soluble fibrin, 112 Adverse cardiovascular events may be triggered by resulting in increases of fibrin split products such as antecedent infections via an increased incidence of throm-D-dimer. These markers are also increased in patients with botic events following infectious diseases [1] [2] [3] . While unstable angina [6] . Lipopolysaccharide (LPS) induced endotoxin responsive elements are currently subject of thrombin generation is considered due to cytokines [7, 8] : intensive investigation in the cardiovascular field [4] , it is while TNF does not contribute [9] , IL-6 may play a pivotal well known that innate immunity and coagulation are role [10] , although experimental proof in humans is still intricately linked [5] .
lacking. Tissue factor forms a highly procoagulant comIn particular, systemic inflammation, including endotoxplex with activated factor VII (FVIIa), which initiates the emia, induces tissue factor. Disseminated intravascular coagulation cascade [11] . Inappropriate in vivo expression coagulation (DIC) causes changes in plasma levels of all of TF on monocytes is not only found in DIC, but also in coagulation factors: clinical studies reported that tissue patients with acute coronary syndrome [12] . Angiotensin-converting enzyme inhibitors (ACE-Is) have become a mainstay in the treatment of hypertension, anti-hypertensive action, numerous reports suggest altercontinued over 8.5 h at 3 ml / kg / h to maintain adequate native mechanisms of action related to the atherothromhydration. Two hours after enalapril (or placebo) intake, botic process. Only recently, an in vitro trial suggested that subjects received a bolus of 2 ng / kg LPS i.v. (National ACE-Is could possibly reduce NF-kB translocation and Reference Endotoxin, Escherichia coli; USP Convention, TF-expression in LPS-stimulated monocytes [13] .
Rockville, MD, USA). This in vitro study provided a model to further investigate whether inhibition of ACE activity could also modu-2 .4. Sampling and analysis late TF-induced coagulation in vivo.
As both NF-kB and TF are attractive targets for the Sampling times were selected based on the kinetics of treatment of DIC [14] and cardiovascular disease in coagulation effects seen in subjects challenged with LPS in general [12] , we investigated whether the ACE-I enalapril previous LPS trials and on the kinetics of TF up-regulation could inhibit TF-induced coagulation in a well stan- [17, 20] . Blood samples were collected by repeated venidardised model [15] of human endotoxemia [16] [17] [18] .
punctures [20] . Cell Thirty healthy male volunteers were invited to particisubpopulations were gated according to their location on pate in this trial. All subjects were 19-35 years of age with the FSC / SSC dot plot, and subsets were then plotted a body mass index between the 15th and the 85th against their fluorescence (FL1 / FL2). Neutrophil counts percentile. Determination of health status included medical were obtained with a cell counter (Sysmex, Milton history, physical examination, laboratory parameters, virKeynes, UK), and monocyte counts were estimated from ological and standard drug screening. In addition, study FSS / SSC flowcytometry counts [20] . subjects were tested for hereditary thrombophilia, i.e.,
The following commercially available assays were used: Factor V Leiden, protein C and S deficiency, to minimise prothrombin fragment F (Behring; Marburg, Germany; 112 potential risks imposed by endotoxin-induced coagulation normal value ,1.9 nmol / l), fibrinolysis was assessed with activation. Exclusion criteria were regular or recent intake the following assays: plasmin-antiplasmin (PAP) comof medication including non-prescription medication, and plexes (Enzygnost PAP micro, Behring; normal range: relevant abnormal findings in medical history or laboratory 120-700 mg / l), measuring plasmin activity; the fibrin split parameters.
product D-dimer (Boehringer Mannheim, Mannheim, Germany; normal values ,400 ng / ml) which reflects fib-2 .3. Study protocol rinolytic digestion of cross-linked fibrin, interleukin-6 (normal range: 0.4-2.2 pg / ml) [21] and tumour necrosis Group A (active) received enalapril 20 mg (Renitec, factor alpha (normal range: 1-6 pg / ml) high sensitivity MSD) for 6 consecutive days (last dose 2 h prior to LPS EIA, R&D Systems, MN, USA). TF levels in human infusion). Group B (single dose group) received placebo plasma were quantified as described previously [22] . ACE for 5 consecutive days and a single dose of 20 mg enalapril activity was measured with an ACE reagent (Sigma on the study day 2 h prior to LPS infusion. Group C Diagnostics, St. Louis, MO, USA) on a Hitachi 911 (control) received placebo only. The experimental proanalyzer. Expected mean values are 30 U / l and the cedures of the endotoxin infusion studies have been coefficients of variation for intra-and inter-assay varidescribed in detail previously [19, 20] . Briefly, volunteers ability were,5%. were admitted to the study ward at 8:00 a.m. after an overnight fast, because the response to endotoxin varies 2 .5. Data analysis with daytime. Throughout the entire study period, subjects were confined to bedrest and kept fasting for 8. 
. Results

.1. Plasma ACE activity
As outlined above our trial included three treatment arms. A single dose of 20 mg enalapril decreased ACE activity by 95% (95% confidence interval: 91-99%; P, 0.01) at 2 h after LPS infusion, i.e., when coagulation starts. Similarly, those subjects, who had ingested enalapril for 5 days prior to the study day, presented with an 80% lower ACE activity on the study day. A further decrease in plasma ACE activity to about 5% of the initial value was seen 4 h after intake of the last tablet.
.2. Effect of enalapril on systemic coagulation
.2.1. Coagulation
Because of difficulties in assessing TF activity on non increased almost 10-fold at 4 h (P,0.001 vs. baseline, Fig.  1 ). D-Dimer increased constantly and peaked fourfold over baseline in the placebo group at 24 h and PAP-levels 2-60%) at 4 h and returned to baseline levels at 24 h increased 4-6-fold at 2 h (P.0.05 between treatment (P5n.s. between groups; data not shown). Twenty-four groups).
hours after LPS infusion, monocyte counts returned to baseline and TF expression was no longer elevated.
.2.2. Cytokine levels
Pre-treatment with enalapril neither affected peak TNF-3 .3.2. Plasma TF levels 296 pg / ml (95% C.I.: 234-359 at 90 min; n530)
Baseline levels of plasma TF averaged 149 pg / ml (95% nor peak IL-6 levels 494 pg / ml (95% C.I. 376-612 at 3 h; C. Baseline values for all parameters were similar in all activated as measured by a threefold increase in CD11b groups. Monocyte counts fell to almost undetectable values expression; yet, mean TF fluorescence intensity of 2 h after LPS infusion, and nearly recovered at 6 h in all peripheral monocytes was only increased by 30% (C.I.: study groups.
.3.4. Mean arterial pressure (MAP)
We had an 80% power to detect a 50% difference in The dose of enalapril given in this trial follows the F levels. This was deemed adequate in view of the 50%
112
European guidelines for treating hypertensive patients. In decrease in TF activity induced by captopril in vitro, and our trial, enalapril did not significantly lower blood the demonstrated .500% increase in thrombin generation pressure of healthy young volunteers under LPS. Overall, between anticoagulants and placebo usually found in this the effects of LPS with and without enalapril on blood model [20] . pressure and heart rate were mild to moderate. Mean basal Another explanation for the lack of effect of enalapril MAP levels were slightly lower in subjects pretreated with may be the differential behaviour of isolated monocytes enalapril (81 mmHg, C.I. 76-86) compared to placebo (86 and monocytes in whole blood [24] . This has been mmHg, C.I. 79-93), and single dose enalapril (87 mmHg demonstrated for different physiological mediators and C.I. 82-93). Minimal MAP levels were reached at 6-7 h drugs. For example, salicylate inhibited TF-expression in in all groups (pretreated 71 mmHg C.I. 61-80, placebo 76 LPS-stimulated isolated monocytes whereas aspirin or mmHg C.I. 69-83, single dose 68 mmHg C.I. 63-73).
salicylate enhanced TF-expression in whole blood, and did MAP levels below 60 mmHg were observed at 7 h in four not affect LPS induced coagulation in vivo [20, [25] [26] [27] [28] . subjects receiving enalapril (three in pretreatment group
The same may hold true for ACE inhibitors. and one with single dose), but in none of the placebo One may criticise the dose of enalapril administered. treated subjects.
However, the selection of the dose was based on a number of large, randomised trials demonstrating a survival advantage like the ACESS [29] and OVERTURE trials [30] administering either 20 mg of enalapril once a day or 10 4 . Discussion mg b.i.d. While Nanas et al. [31] described a multicentre trial with It has been reported that ACE inhibitors decrease LPS high dose enalapril of 60 mg once compared to 20 mg in induced NF-kB translocation and hence TF-activity in patients with congestive heart failure, it did not yield human monocytes [13] . Based on this in vitro study, we significant differences either in mortality or in HR and hypothesised that inhibition of ACE activity could translate SBP between treatment groups. Thus the dose was based into inhibition of LPS-induced TF-triggered coagulation.
on large randomised controlled trials (RCTs). Additionally, We therefore used the human endotoxin model, which we did not intend to further increase the dose of enalapril, unequivocally induces TF-mediated coagulation [16] [17] [18] . because this may adversely affect blood pressure. We As expected, we observed only a small TF-up-regulation considered that the minimal MAP should not decreased on circulating monocytes by flowcytometry despite marked below 60 mmHg because this MAP is regarded the activation of monocytes as measured by the increase in minimum necessary for adequate renal perfusion and CD11b expression. The reason for this phenomenon could indeed MAP values fell below 60 mmHg in four out of 20 be the margination of TF positive monocytes in the volunteers receiving enalapril but in none of the placebo microvasculature including the lung, which was observed group. Besides, we assumed that this problem may be in a mouse endotoxemia model (Luther et al., unpublished accentuated in septic patients, who are hypotensive. data). Therefore, in vivo activated TF-expressing monoAlthough our findings are mainly negative, they may cytes are not accessible by flow cytometric analysis. Well still have clinical implications. First ACE-Is may be safely aware of this limitation, we focused on the LPS effect on used in patients with cardiovascular disease, even if they downstream coagulation as measured by F and D-dimer are critically ill. The unaltered coagulation and fibrinolysis 112 levels. As shown in Fig. 1 , prothrombin fragment inprofile in response to systemic inflammation contributes to creased about 10 fold in all treatment groups. Similarly, a good safety profile. Secondly, it has been suggested that enalapril did not alter the LPS induced PAP-release.
adverse cardiovascular events may be triggered by anteceHence contrary to the in vitro study [13] enalapril was dent infections. From our data it can be anticipated that the not able to blunt TF-triggered coagulation in vivo. This use of ACE-Is will not lower the increased incidence of could be due to the enalapril dose administered to our thrombotic events following infectious diseases [1] [2] [3] . The volunteers. The 20 mg enalapril dose is expected to yield concept of ACE-Is in DIC was initially supported by an plasma enalaprilat concentrations of ,0.1 mg / ml, which animal trial. The trial describing the effects of captopril however were ineffective in vitro [13] . Yet, the adminiswas performed in an intravascular coagulation model in tered dose of enalapril is the highest recommended dose rats [32] . The amount of fibrin measured was significantly according to the Austrian summary of product characterislower in thrombin challenged animals treated with captoptics, and we achieved 95% inhibition of ACE activity. This ril compared to controls. However, our own data do not indicates that clinically relevant suppression of ACE support the concept that the selected ACE-I (enalapril) activity does not alter LPS-induced, TF-mediated coagulawould be beneficial in endotoxin induced DIC or other tion in humans. As this is a negative finding, we have coagulopathies. performed a power calculation.
In conclusion, our trial provides evidence against a inhibitor dose-dependently inhibits coagulation activation without modulatory role of ACE in LPS-induced, TF-triggered influencing the fibrinolytic and cytokine response during human coagulation. 
